Biotech Values

[DewDiligence]

New IDIX Director

Pursuant to the amended NVS-IDIX relationship inked in May, which entitles NVS to name three of the nine directors* on IDIX’s BoD (#msg-37998991), NVS has designated Anthony Rosenberg as its third director:

http://sec.gov/Archives/edgar/data/1093649/000114420409030761/v151412_8k.htm

Here is some biographical info on Mr. Rosenberg:

http://bioasia.bio.org/opencms/bioasia/2007/program/bio_AR_Oct_06.pdf

Rosenberg has been head of Business Development and Licensing at NVS since 2005 and is a member of CEO Dan Vasella’s inner circle. He joined Sandoz (NVS’ predecessor company) in 1980 in the UK, where he held various leadership positions in sales and marketing, business development, and strategic planning. In 1994, Rosenberg moved to Basel, Switzerland (NVS’ HQ location) as product manager for Clozaril. He became head of Global Marketing Primary Care and later was head of the Transplant and Immunology business unit.

During Rosenberg’s tenure, NVS has been among the most active Big Pharma in licensing and M&A. Rosenberg has overseen major licensing transactions in the respiratory, dermatology, CNS, transplant, ophthalmology, and antiviral areas.

Rosenberg has a BSc in biology from University of Leicester (UK) and an MSc in physiology from University of London.

NVS’ two other designates on IDIX’s BoD are Robert Pelzer, general counsel of NVS’ US subsidiary, and Steven Projan, head of NVS’ R&D team in infectious diseases.

*Contrary to what was posted previously, the BoD is not being expanded from nine to ten directors; rather, Anthony Rosenberg is filling the existing open slot on the nine-member BoD.